View Older Stories
-
Canaccord Genuity Reiterates Buy Rating on Guardant Health (GH)
-
Guardant Health posts 39% revenue growth in fourth quarter
-
Guardant Health (GH) PT Raised to $120 at Stifel: Poised for Solid Volume, ASP Growth
-
Guardant Health (GH) PT Raised to $130 at Jefferies
-
BTIG: 'we name GH and WGS as 2026 Top Picks'
-
Guardant Health launches liquid biopsy testing at Italian hospital
-
Guardant Health expands blood test for late-stage cancer monitoring
-
Guardant Health (GH) PT Raised to $115 at Raymond James
-
Guardant Health (GH) PT Raised to $100 at TD Cowen
-
Guardant Health (GH) PT Raised to $100 at BofA Securities
-
Guardant Health (GH) PT Raised to $100 at Canaccord Genuity
-
Guardant Health (GH) PT Raised to $90 at Wolfe Research
-
Guardant Health (GH) PT Raised to $100 at BTIG, Top Pick
-
Guardant Health (GH) PT Raised to $100 at Citi
-
Nephron Upgrades Guardant Health (GH) to Hold
-
Guardant Health (GH) Tops Q3 EPS by 40c, Offers Guidance
-
Guardant Health partners with Zephyr AI for cancer biomarker research
-
Bernstein 'Positive' on Guardant Health (GH) Post 2025 Investor Day
-
Guardant Health (GH) Raised to PT $70 at JP Morgan
-
Guardant Health (GH) PT Raised to $67 at Guggenheim
-
Guardant Health (GH) PT Raised to $72 at TD Cowen
-
Guardant Health (GH) PT Raised to $70 at Mizuho
-
Canaccord Genuity Reiterates Buy Rating on Guardant Health (GH)
-
Guardant Health (GH) PT Raised to $75 at Leerink Partners
-
Wolfe Research Upgrades Guardant Health (GH) to Outperform, 'We have been wrong on GH over the past year'
-
Guardant Health (GH) PT Raised to $70 at Stifel
-
Guardant Health (GH) PT Raised to $80 at BTIG
-
UBS Reiterates Buy Rating on Guardant Health (GH)
-
Canaccord Genuity Reiterates Buy Rating on Guardant Health (GH)
-
BTIG Reiterates Top Pick on Guardant Health (GH)
-
Wells Fargo Resumes Guardant Health (GH) at Overweight
-
Guardant Health partners with PathGroup to expand Shield blood test access
-
Guardant Health (GH) PT Raised to $70 at BTIG
-
Evercore ISI Reiterates Outperform Rating on Guardant Health (GH)
-
Leerink Partners Reiterates Outperform Rating on Guardant Health (GH)
-
Raymond James Reiterates Outperform Rating on Guardant Health (GH)
-
Guardant Health reports improved Shield cancer test performance
-
Guardant Health (GH) surges in after-hours trade
-
Guardant Health (GH) PT Raised to $60 at Scotiabank
-
Guardant Health (GH) Tops Q2 EPS by 28c, provides guidance
-
Evercore ISI Reiterates Outperform Rating on Guardant Health (GH)
-
Braidwood ruling positive for Exact Sciences (EXAS) and Guardant Health (GH) - Stifel
-
Supreme Court Braidwood ruling positive for Guardant Health (GH) and Exact Sciences (EXAS) - Barclays
-
Guardant Health (GH) PT Raised to $65 at Mizuho
-
UBS Reiterates Buy Rating on Guardant Health (GH)
-
Guardant Health (GH) Granted FDA Breakthrough Device Designation for Multi-Cancer Detection (MCD) Test
-
Leerink Partners Reiterates Outperform Rating on Guardant Health (GH)
-
Raymond James Reiterates Outperform Rating on Guardant Health (GH)
-
Citi names 3 stocks as its new top picks in the Life Science sector
-
Guardant Health (GH) announces new features for Guardant 360 Liquid test

